See more : Aquestive Therapeutics, Inc. (AQST) Income Statement Analysis – Financial Results
Complete financial analysis of Atreca, Inc. (BCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Atreca, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SaveLend Group AB (publ) (YIELD.ST) Income Statement Analysis – Financial Results
- Ficont Industry (Beijing) Co., Ltd. (605305.SS) Income Statement Analysis – Financial Results
- Verecloud, Inc. (VCLD) Income Statement Analysis – Financial Results
- Silicon Power Computer & Communications Inc. (4973.TWO) Income Statement Analysis – Financial Results
- PT Austindo Nusantara Jaya Tbk (ANJT.JK) Income Statement Analysis – Financial Results
Atreca, Inc. (BCEL)
About Atreca, Inc.
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 770.00K | 851.00K | 1.35M | 2.13M | 0.00 | 0.00 |
| Cost of Revenue | 7.08M | 77.00K | 22.00K | 122.00K | 0.00 | 0.00 |
| Gross Profit | -6.31M | 774.00K | 1.33M | 2.01M | 0.00 | 0.00 |
| Gross Profit Ratio | -819.61% | 90.95% | 98.37% | 94.28% | 0.00% | 0.00% |
| Research & Development | 66.83M | 78.35M | 62.05M | 54.73M | 32.51M | 24.87M |
| General & Administrative | 31.47M | 31.95M | 26.83M | 17.85M | 7.06M | 4.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.47M | 31.95M | 26.83M | 17.85M | 7.06M | 4.56M |
| Other Expenses | 770.00K | 851.00K | 1.35M | 2.13M | 961.00K | 1.72M |
| Operating Expenses | 98.30M | 110.30M | 88.88M | 72.57M | 39.57M | 29.44M |
| Cost & Expenses | 98.30M | 110.30M | 88.88M | 72.57M | 39.57M | 29.44M |
| Interest Income | 817.00K | 207.00K | 1.22M | 3.21M | 714.00K | 152.00K |
| Interest Expense | 0.00 | 3.00K | 4.00K | 6.00K | 9.00K | 14.00K |
| Depreciation & Amortization | 7.08M | 4.55M | 2.38M | 1.70M | 1.41M | 1.21M |
| EBITDA | -90.44M | -104.70M | -83.93M | -67.22M | -37.20M | -26.51M |
| EBITDA Ratio | -12,559.48% | -12,837.25% | -6,203.33% | -3,150.14% | 0.00% | 0.00% |
| Operating Income | -103.79M | -113.80M | -86.31M | -68.92M | -39.57M | -29.44M |
| Operating Income Ratio | -13,479.09% | -13,371.92% | -6,379.01% | -3,229.66% | 0.00% | 0.00% |
| Total Other Income/Expenses | 368.00K | 978.00K | 1.19M | 5.09M | 1.63M | 1.91M |
| Income Before Tax | -97.16M | -109.33M | -86.33M | -67.48M | -37.94M | -27.52M |
| Income Before Tax Ratio | -12,617.79% | -12,846.65% | -6,380.93% | -3,162.28% | 0.00% | 0.00% |
| Income Tax Expense | -6.63M | 1.00K | 1.00K | 1.00K | -1.00K | 3.00K |
| Net Income | -90.53M | -109.33M | -86.34M | -67.48M | -37.94M | -27.53M |
| Net Income Ratio | -11,756.49% | -12,846.77% | -6,381.01% | -3,162.32% | 0.00% | 0.00% |
| EPS | -2.35 | -2.95 | -2.70 | -4.26 | -11.75 | -12.44 |
| EPS Diluted | -2.35 | -2.95 | -2.70 | -4.26 | -11.75 | -12.44 |
| Weighted Avg Shares Out | 38.59M | 37.04M | 31.92M | 15.83M | 3.23M | 2.21M |
| Weighted Avg Shares Out (Dil) | 38.59M | 37.04M | 31.92M | 15.83M | 3.23M | 2.21M |
Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Atreca: Safety Data Brought Down Stock
Atreca to Present at Upcoming Virtual Investor Conferences
Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
Atreca to Present at Upcoming Virtual Investor Conferences
BCEL Stock Fell Over 38% Intraday: Why It Happened
Atreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101
Atreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady to its Board of Directors
20 Short Ideas With Super-Weak Momentum
Atreca Reports First Quarter 2021 Financial Results and Recent Corporate Developments
Source: https://incomestatements.info
Category: Stock Reports